NasdaqCM:AXGNMedical Equipment
Is Axogen’s Upgraded Outlook And Avance BLA Progress Altering The Investment Case For Axogen (AXGN)?
Axogen recently reported strong second-quarter 2025 results, highlighting double-digit sales growth across its nerve repair markets and reaffirming progress toward anticipated September 2025 Biologics License Application approval for Avance Nerve Graft, which would provide 12 years of market exclusivity.
The combination of upgraded full-year revenue guidance, expectations for net cash flow positivity in 2025, and continued investment in innovation and commercial expansion underscores how...